Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers.
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers. from Times of India https://ift.tt/In3lKPz
Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an average 12% body weight loss in a Phase 3 trial. The study, involving overweight or obese adults, revealed significant weight reduction and improved cardiovascular markers. from Times of India https://ift.tt/In3lKPz
Comments
Post a Comment